vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and BANCFIRST CORP (BANF). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $181.0M, roughly 1.4× BANCFIRST CORP). BANCFIRST CORP runs the higher net margin — 32.9% vs 11.1%, a 21.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 11.1%). BANCFIRST CORP produced more free cash flow last quarter ($237.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 9.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
BancFirst Corporation is an Oklahoma-based financial services holding company. The company operates three subsidiary banks, BancFirst, an Oklahoma state-chartered bank; and Pegasus Bank and Worthington Bank, both Texas state-chartered banks.
ANIP vs BANF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $181.0M |
| Net Profit | $27.5M | $59.5M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 41.6% |
| Net Margin | 11.1% | 32.9% |
| Revenue YoY | 29.6% | 11.1% |
| Net Profit YoY | 367.5% | 5.3% |
| EPS (diluted) | $1.14 | $1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $181.0M | ||
| Q3 25 | $227.8M | $175.5M | ||
| Q2 25 | $211.4M | $169.3M | ||
| Q1 25 | $197.1M | $164.8M | ||
| Q4 24 | $190.6M | $162.9M | ||
| Q3 24 | $148.3M | $163.7M | ||
| Q2 24 | $138.0M | $153.8M | ||
| Q1 24 | $137.4M | $151.0M |
| Q4 25 | $27.5M | $59.5M | ||
| Q3 25 | $26.6M | $62.7M | ||
| Q2 25 | $8.5M | $62.3M | ||
| Q1 25 | $15.7M | $56.1M | ||
| Q4 24 | $-10.3M | $56.5M | ||
| Q3 24 | $-24.2M | $58.9M | ||
| Q2 24 | $-2.3M | $50.6M | ||
| Q1 24 | $18.2M | $50.3M |
| Q4 25 | 14.1% | 41.6% | ||
| Q3 25 | 15.9% | 45.0% | ||
| Q2 25 | 6.6% | 47.1% | ||
| Q1 25 | 13.3% | 43.1% | ||
| Q4 24 | -2.3% | 44.2% | ||
| Q3 24 | -13.8% | 45.2% | ||
| Q2 24 | 3.7% | 42.4% | ||
| Q1 24 | 14.8% | 42.5% |
| Q4 25 | 11.1% | 32.9% | ||
| Q3 25 | 11.7% | 35.7% | ||
| Q2 25 | 4.0% | 36.8% | ||
| Q1 25 | 8.0% | 34.0% | ||
| Q4 24 | -5.4% | 34.7% | ||
| Q3 24 | -16.3% | 36.0% | ||
| Q2 24 | -1.7% | 32.9% | ||
| Q1 24 | 13.2% | 33.3% |
| Q4 25 | $1.14 | $1.75 | ||
| Q3 25 | $1.13 | $1.85 | ||
| Q2 25 | $0.36 | $1.85 | ||
| Q1 25 | $0.69 | $1.66 | ||
| Q4 24 | $-0.45 | $1.68 | ||
| Q3 24 | $-1.27 | $1.75 | ||
| Q2 24 | $-0.14 | $1.51 | ||
| Q1 24 | $0.82 | $1.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.9B |
| Total Assets | $1.4B | $14.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | $540.7M | $1.9B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.7B | ||
| Q4 24 | $403.7M | $1.6B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.5B | ||
| Q1 24 | $452.0M | $1.5B |
| Q4 25 | $1.4B | $14.8B | ||
| Q3 25 | $1.4B | $14.2B | ||
| Q2 25 | $1.3B | $14.0B | ||
| Q1 25 | $1.3B | $14.0B | ||
| Q4 24 | $1.3B | $13.6B | ||
| Q3 24 | $1.3B | $13.3B | ||
| Q2 24 | $920.8M | $12.7B | ||
| Q1 24 | $914.5M | $12.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $285.3M |
| Free Cash FlowOCF − Capex | $29.1M | $237.0M |
| FCF MarginFCF / Revenue | 11.8% | 130.9% |
| Capex IntensityCapex / Revenue | 0.5% | 26.7% |
| Cash ConversionOCF / Net Profit | 1.10× | 4.79× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $430.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $285.3M | ||
| Q3 25 | $44.1M | $75.4M | ||
| Q2 25 | $75.8M | $78.1M | ||
| Q1 25 | $35.0M | $77.0M | ||
| Q4 24 | $15.9M | $261.2M | ||
| Q3 24 | $12.5M | $77.6M | ||
| Q2 24 | $17.4M | $100.2M | ||
| Q1 24 | $18.3M | $66.3M |
| Q4 25 | $29.1M | $237.0M | ||
| Q3 25 | $38.0M | $63.7M | ||
| Q2 25 | $71.8M | $64.4M | ||
| Q1 25 | $32.5M | $65.6M | ||
| Q4 24 | $13.5M | $224.5M | ||
| Q3 24 | $7.7M | $72.4M | ||
| Q2 24 | $13.0M | $94.1M | ||
| Q1 24 | $13.7M | $56.1M |
| Q4 25 | 11.8% | 130.9% | ||
| Q3 25 | 16.7% | 36.3% | ||
| Q2 25 | 34.0% | 38.0% | ||
| Q1 25 | 16.5% | 39.8% | ||
| Q4 24 | 7.1% | 137.8% | ||
| Q3 24 | 5.2% | 44.2% | ||
| Q2 24 | 9.4% | 61.2% | ||
| Q1 24 | 10.0% | 37.1% |
| Q4 25 | 0.5% | 26.7% | ||
| Q3 25 | 2.7% | 6.7% | ||
| Q2 25 | 1.9% | 8.1% | ||
| Q1 25 | 1.3% | 6.9% | ||
| Q4 24 | 1.3% | 22.5% | ||
| Q3 24 | 3.2% | 3.2% | ||
| Q2 24 | 3.2% | 3.9% | ||
| Q1 24 | 3.3% | 6.8% |
| Q4 25 | 1.10× | 4.79× | ||
| Q3 25 | 1.66× | 1.20× | ||
| Q2 25 | 8.87× | 1.25× | ||
| Q1 25 | 2.23× | 1.37× | ||
| Q4 24 | — | 4.62× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | 1.00× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
BANF
Segment breakdown not available.
